SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Barbara Jordan — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientBarbara Jordan
Date of birth1936-02-21
IdentifiersMRN HR-ML030-SYN-TD; SSN (made up) 000-30-6852
Document date1980-06-29
AuthorEvangeline Moss, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood. [S]

History of Present Illness

Ms. Jordan returns six weeks after her second ocrelizumab half-dose. During the first infusion she had a scratchy throat that settled when the infusion was slowed; the second infusion went without a reaction. She has had no infections, cold sores, or diarrhea. Physical therapy started four weeks ago through a second provider, after the first service could not offer a date; she has had six sessions and does her home program most days, and she now uses a rollator at home for longer distances. Summer has brought heat sensitivity: her legs feel heavier on hot afternoons and recover when she cools down, and she has started using a cooling vest. She gets up once a night or less. Her mood is steady. [S]

ElementDetail
InfusionsMild throat irritation with the first, settled by slowing; none with the second
InfectionsNone
Physical therapyStarted four weeks ago through a second provider; six sessions
HeatLegs heavier on hot afternoons, recover with cooling
MoodPHQ-9 3

Review of Systems

SystemResultFinding
ConstitutionalPositiveAfternoon fatigue, worse in the heat; no fever
GastrointestinalNegativeNo diarrhea or abdominal pain
GenitourinaryNegativeUp once a night or less; no burning
IntegumentaryNegativeNo rash or cold sores
NeurologicalPositiveTemporary heaviness of the legs in the heat; no new symptom lasting more than a day
PsychiatricNegativeMood steady

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol (vitamin D3) 1954 units (50 mcg) oral capsule, one capsule dailyOne capsule dailyOral route1980-03-02activeS
Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once toleratedOne tablet three times a dayOral route1980-03-16 to 1980-04-20completedS
Baclofen 10 mg oral tablet, one tablet three times a dayOne tablet three times a dayOral route1980-04-20activeS
Mirabegron 25 mg extended-release oral tablet, one tablet dailyOne tablet dailyOral route1980-03-16activeS
Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center300 mg on day 1 and day 15 (given), then 600 mg every 6 monthsIntravenous route1980-05-04activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1980-06-29Body height173cmS
1980-06-29Body weight83.5kgS
1980-06-29Body mass index (BMI) [Ratio]27.9kg/m2S
1980-06-29Systolic blood pressure118mm[Hg]S
1980-06-29Diastolic blood pressure74mm[Hg]S
1980-06-29Heart rate74/minS
1980-06-29Respiratory rate16/minS
1980-06-29Body temperature36.8CelS
1980-06-29Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1980-06-29Leukocytes [#/volume] in Blood by Automated count5.910*3/uL4-11 10*3/uLNormalS
1980-06-29Lymphocytes [#/volume] in Blood by Automated count1.410*3/uL1-4.8 10*3/uLNormalS
1980-06-29Hemoglobin [Mass/volume] in Blood13.4g/dL12-15.5 g/dLNormalS
1980-06-29Platelets [#/volume] in Blood by Automated count24810*3/uL150-400 10*3/uLNormalS
1980-06-29CD19 cells [#/volume] in Blood3/uLExpected to be depleted after an anti-CD20 therapyLowS
1980-06-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L7-35 U/LNormalS
1980-06-2925-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30-100 ng/mLNormalS
1980-06-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 1980-06-29; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 118/74, pulse 74; temperature 36.8 °C
NeurologicalSpastic gait with a cane, as before; modified Ashworth 1+ in both legs; EDSS 6.0; timed 25-foot walk 11.1 seconds
SkinNo rash

Problems

ProblemClinical statusVerificationCodeProvenance
Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spineresolvedconfirmed G35.DS — Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts.
Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 1971 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosisactiveconfirmed G35.B1S — Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts.
Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of fallsactiveconfirmed R26.89S — Synthetic modern coding anchored to her documented cane.
Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residualactiveconfirmed N31.9S — Synthetic; common in multiple sclerosis. No public source describes her bladder.
Vitamin D deficiencyactiveconfirmed E55.9S — Synthetic laboratory finding at intake.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationNew or worsening symptoms (relapse, pseudo-relapse with heat or infection)Every visitCompleted todayNo relapse; heat-related pseudo-relapse explained
ExaminationDisability: EDSS and timed 25-foot walkEvery visit, and at least every 6 monthsCompleted todayEDSS 6.0; timed 25-foot walk 11.1 seconds
Medication safetyInfusion reactions and infectionsEach infusion, and every visitCompleted todayMild throat irritation with the first infusion, settled by slowing; none with the second; no infections since
LaboratoryBlood count with absolute lymphocytesBefore the first dose, then before each doseCompleted todayWhite cells 5.9, lymphocytes 1.4, hemoglobin 13.4, platelets 248; CD19 3 per microliter (depleted, expected)
LaboratoryLiver testsBefore the first dose, then with symptoms and before each doseCompleted todayALT 20 U/L
LaboratoryHepatitis B surface antibody after vaccinationOne to two months after the series in someone on immune therapyCompleted todayProtective level after two doses
ExaminationSpasticity (modified Ashworth) and baclofen toleranceEvery visitCompleted todayModified Ashworth 1+ on baclofen 10 mg three times a day
ExaminationBladder: urgency, nocturia, urinary infection, and blood pressure on mirabegronEvery visitCompleted todayNocturia once or less; blood pressure 118/74 on mirabegron
ReferralFalls, walking aids and physical therapyEvery visitCompleted todayPhysical therapy started four weeks ago through a second provider; rollator at home; no falls
Self-managementFatigue and heat sensitivityEvery visitCompleted todayHeat sensitivity; cooling vest started
Laboratory25-hydroxyvitamin DAt baseline, 8 to 12 weeks after repletion, then yearlyCompleted today34 ng/mL after repletion
ImagingBone densityOnce for reduced mobility and earlier steroid courses; repeat by riskDueAt the preventive visit
SurveyDepression screen (PHQ-9)At intake, then every 6 months and with any changeCompleted todayPHQ-9 3
ExaminationConcentration and word-findingAt intake, then yearly or with concernCompleted todayNo concern raised by her; lectures and writing unaffected
Medication safetyBreast cancer screening (ocrelizumab label: standard screening)Every two years from 40DueMammogram to be ordered at the preventive visit

Goal progress:

Guideline basis: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); OCREVUS (ocrelizumab) injection, prescribing information (2026); Multiple sclerosis in adults: management (NG220) (2022); Adult Immunization Schedule by Age (2026); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026)

Follow-up: Preventive visit in seven weeks with bone density and the mammogram order. Re-baseline brain MRI and review in four months, before the 600 mg dose. Next scheduled visit 1980-08-17: periodic adult preventive visit. [S]